Related Experiment Videos
Metabolic effects of prazosin.
Clinical Pharmacology and Therapeutics
|March 1, 1980
Summary
Prazosin increased plasma glucose and free fatty acids in hypertensive patients, regardless of glucose tolerance. This contrasts with some other alpha-adrenergic blockers, suggesting unique metabolic effects.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Research
Background:
- Hypertension management often involves medications with potential metabolic side effects.
- Alpha-adrenergic blockers are used for hypertension, but their impact on glucose metabolism requires further elucidation.
Purpose of the Study:
- To investigate the metabolic and endocrine effects of prazosin in hypertensive patients.
- To compare the metabolic impact of prazosin with other alpha-adrenergic blockers.
Main Methods:
- Oral administration of 2 mg prazosin to 12 hypertensive patients.
- Assessment of metabolic and endocrine variables, including plasma glucose, serum free fatty acids (FFA), albumin, growth hormone (GH), prolactin (PRL), and gastrin.
- Patients were categorized into normal and abnormal glucose tolerance groups.
Main Results:
- Prazosin administration led to increased plasma glucose and serum FFA in both normal and diabetic hypertensive subjects.
- A trend towards increased serum albumin (IRI) was observed.
- No significant changes were noted in growth hormone (GH), prolactin (PRL), or gastrin levels.
Conclusions:
- Prazosin exhibits distinct metabolic effects, notably increasing plasma glucose and FFA.
- These findings align with some alpha-adrenergic blockers but differ from phentolamine regarding glucose response.
- Further research into prazosin's specific metabolic profile is warranted for hypertensive patients.